Abstract
The novel coronavirus SARS-CoV-2 appeared at the end of 2019, spreading rapidly and causing a severe respiratory syndrome (COVID-19) with high mortality. Until a vaccine or therapy is found, the most effective method of prophylaxis has been to minimize transmission through mandatory social distancing and restriction of all but essential economic activity. A key question facing policy makers and individuals is when to resume economic and social activity in the face of persistent community transmission of SARS-CoV-2. To help address this question, we have developed a mathematical model of transmission and mortality of COVID-19 in countries that have implemented stringent social distancing measures. Using data from Italy, Spain, Switzerland and Germany on SARS-CoV-2 transmission, active caseload and mortality, we model the rapid rise and slow decay (“long tail”) of the COVID-19 pandemic using a first order nonlinear differential equation. The prognostic utility of our model is validated by strong correspondence between predicted and prospectively observed data up to eight weeks after curve fitting. This Double Power Law model can be applied to other countries as a predictive tool to inform policy decisions concerning social distancing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received to support this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is an analysis of epidemiological data and thus does not require IRB oversight.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
- revisions for clarity - additional data on case incidence and mortality
Data Availability
Data is drawn from Johns Hopkins Coronavirus Resource Center and compiled on https://www.worldometers.info/coronavirus/
